Cybin Inc. Executives to Present at TD Cowen Neuropsychiatry & Epilepsy Summit
TL;DR
Cybin's executives will discuss their breakthrough therapy drugs at a key summit, offering investors early insights into potential market advantages in neuropsychiatry treatments.
Cybin's CMO and CBO will participate in a fireside chat at TD Cowen's neuropsychiatry summit on September 17, 2025, at 9:20 a.m. ET.
Cybin is developing novel mental health treatments that could provide effective and durable results for patients suffering from depression and anxiety disorders.
Cybin is pioneering deuterated psychedelic compounds like CYB003 and CYB004 that are advancing through clinical trials with FDA breakthrough designation.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 9:20 a.m. ET. This presentation provides an opportunity for the company to showcase its progress in developing next-generation mental health treatments to investors and industry professionals.
The company is focused on revolutionizing mental healthcare by addressing the large unmet need for effective treatments. Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies.
Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of neuropsychiatry innovation. These developments represent significant advancements in mental health treatment options that could provide more effective and durable results for patients worldwide.
The participation in the TD Cowen summit allows Cybin to communicate its progress and strategic direction directly to the investment community and healthcare professionals. For investors seeking current information about the company, news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the executive presentation can be viewed at https://ibn.fm/KXmrj.
This presentation comes at a critical time for mental health treatment development, as the global need for innovative solutions continues to grow. Cybin's work in developing novel psychedelic-based therapies represents a promising approach to addressing mental health conditions that have historically been difficult to treat effectively. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland demonstrates its global commitment to advancing neuropsychiatry treatments.
Curated from InvestorBrandNetwork (IBN)
